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S UMMA R Y
S E T T I NG AND OB J E C T I V E : To investigate the sensitiv-
ity of the new interferon-gamma release assay (IGRA),
QuantiFERONw-TB Gold Plus (QFT-Plus), for active
TB (used as a surrogate for latent tuberculous infection)
in a Zambian TB clinic.
D E S I G N : Consecutive smear or Xpertw MTB/RIF-
positive adult (age 718 years) pulmonary TB patients
were recruited between June 2015 and March 2016.
Venous blood was tested using QFT-Plus. The sensitivity
was defined as the number positive divided by the total
number tested. Using logistic regression, factors associ-
ated with positive QFT-Plus results were explored.
R E S U LT S : Of 108 patients (median age 32 years,
interquartile range 27–38; 73% male; 63% human
immunodeficiency virus [HIV] positive), 90 were QFT-
Plus-positive, 11 were negative and seven had indeter-
minate results; sensitivity was 83% (95%CI 75–90).
There was no difference in sensitivity by HIV status
(HIV-positive 85%, 95%CI 75–93; n ¼ 68 vs. HIV-
negative 80%, 95%CI 64–91; n ¼ 40; P ¼ 0.59). In
models adjusted for age alone, CD4 cell count ,100
cells/ll (OR 0.15, 95%CI 0.02–0.96; P¼0.05) and body
mass index ,18.5 kg/m2 (OR 0.27, 95%CI 0.08–0.91;
P ¼ 0.02) were associated with decreased odds of
positive QFT-Plus results.
CONC LU S I ON : Overall, the sensitivity of QFT-Plus is
similar to that of the tuberculin skin test and other
IGRAs. While overall sensitivity is not affected by HIV
status, QFT-Plus sensitivity was lower among people
living with HIV/acquired immune-deficiency syndrome
with severe immunosuppression.
K E Y WORD S : interferon-gamma release assays; latent
tuberculous infection; validity
THE INCREASED RISK of active tuberculosis (TB)
among people living with human immunodeficiency
virus/acquired immune-deficiency syndrome
(PLHIV)1,2 can be substantially decreased by treating
latent tuberculous infection (LTBI) with isoniazid
preventive therapy (IPT).3 However, there are numer-
ous barriers to IPTuse,4,5 including the lack of a good
diagnostic test for LTBI among PLHIV.6
Two imperfect but widely used tests for LTBI that
measure the host’s cell-mediated immune response to
Mycobacterium tuberculosis antigens are the tuber-
culin skin test (TST) and interferon-gamma (IFN-c)
release assays (IGRAs) (QuantiFERONw-TB Gold In-
Tube [QGIT], QIAGEN, Hilden, Germany; and the
T-SPOTw.TB test, Oxford Immunotec, Abingdon,
UK).6,7 Both tests have poor and comparable
sensitivity among PLHIV (TST sensitivity 45% and
IGRA sensitivity 60–75%).7–9
CD4þ T-lymphocytes play a critical role in the
immunological control ofM. tuberculosis through the
secretion of IFN-c;10 QGIT mainly evokes and
measures this CD4-mediated response.11 There is
growing evidence to suggest that CD8þT-lymphocytes
also play a role inM. tuberculosis control through the
production of IFN-c,10,12–14 and M. tuberculosis-
specific CD8þ T-lymphocytes have been identified in
subjects with LTBI and active TB.14,15 The QGIT has
thus now been modified to include two antigen
tubes—TB1, which contains a long peptide cocktail
aimed at stimulating CD4þ T-lymphocytes, and TB2,
which contains an additional shorter peptide cocktail
aimed at stimulating CD8þT-lymphocytes in addition
to CD4þ T-lymphocytes16—now called QuantiFER-
ONw-TB Gold Plus (QFT-Plus). The antigen TB 7.7,
found in QGIT, has been removed.16 This approach,
which negates the dependence on CD4-mediated
responses alone, could potentially increase the test’s
validity for LTBI among PLHIV.
We conducted a study in Lusaka, Zambia, a setting
with high TB and HIV prevalence, to determine the
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sensitivity of QFT-Plus. As a gold standard for LTBI
does not exist, active TB was used as a surrogate, as
patients with active TB are infected with M.
tuberculosis.
METHODS
Study population and procedures
The study was based in a government health facility.
All patients with suspected pulmonary TB underwent
sputum testing with either fluorescent microscopy or
the XpertwMTB/RIF assay (Cepheid, Sunnyvale, CA,
USA); pulmonary TB was defined as at least one
positive sputum sample on either smear or Xpert.
Culture is not routinely performed. HIV counselling
and testing according to national guidelines is
routinely offered to all patients investigated and/or
treated for TB. For HIV testing, sequential blood-
based rapid antibody tests with DeterminewHIV-1/2
Antibody (Alere, Waltham, MA, USA) is used first,
which, if reactive, is followed by the Uni-GoldTM
Recombigen HIV-1/2 Antibody test (Trinity Biotech,
Bray, Ireland).17
Between June 2015 and March 2016, consecutive
adult (age718 years) pulmonary TB patients whowere
62 days from starting anti-tuberculosis treatment were
recruited for the study. Written voluntary informed
consent was provided by all study participants.
Information on demographics (age, sex), TB and HIV
diagnosis and physical measurements (height and
weight) were obtained. Bodymass index (BMI), defined
as (weight in kg)/(height in m)2, was classed into
standard categories (,18.5 underweight, 18.5–24.9
normal weight, 25–29.9 overweight,730 obese).18
Venous blood for testingwithQFT-Plus was collected
into lithium heparin tubes, stored at room temperature
and transported within 8 h to the laboratory for
processing according to the manufacturer’s specifica-
tion.16 Venous blood was also collected for CD4 cell
count estimation if patients were HIV-co-infected.
Laboratory procedures
Blood (1 ml) was transferred to each of the four QFT-
Plus tubes (nil [background], TB1 [CD4-mediated
response], TB2 [CD4- and CD8-mediated response]
and mitogen [positive control]), and incubated at
378C for 16–24 h within 16 h of collection. Following
incubation, the samples were returned to ambient
room temperature and centrifuged at 2000–3000
relative centrifugal force for 15 min. Plasma was
extracted and transferred to a808C freezer. Enzyme-
linked immunosorbent assay (ELISA) was performed,
following re-centrifugation of plasma using standard
test kits. The ELISA plate was read at wavelengths of
450 nm and 650 nm. Data were transferred to the
QFT-Plus analysis software to calculate results.
Positive results were defined according to the
manufacturer’s threshold (70.35 international unit
[IU]/ml); a positive result on either antigen tube, TB1
or TB2, was considered positive. The upper limit for
quantifying IFN-c concentrations was 10 IU/ml. T-
lymphocyte estimation (CD4þ, CD8þ and CD3þ) was
performed within 48 h of blood collection using BD
FACSCount reagents and a BD FACSCount flow-
cytometer (BD, Sparks, MD, USA), according to the
manufacturer’s specification. The upper limit for
CD8 cell count measurement was 2000 cells/ll.
Patient follow-up
To explore whether negative/indeterminate QFT-Plus
results were due to TB and/or HIV-associated immu-
nosuppression, which should improve upon treatment,
patients with negative or indeterminate QFT-Plus
results at enrolment underwent repeat testing with
QFT-Plus at ~1–2 months post-enrolment.
Statistical analysis
The target sample size was 100 pulmonary TB
patients, aiming to determine an overall QFT-Plus
sensitivity of 74% (based on QGIT sensitivity in this
population11) with a precision of 69% assuming
95% confidence intervals (CIs). A higher sensitivity
of 85% would give a precision of 67%.
Data were analysed using STATA, version 12.0
(StataCorp LP, College Station, TX, USA). Sensitivity
was defined as the number of positive results divided
by the total number tested at enrolment; the denom-
inator included indeterminate results. To explore
factors associated with positive QFT-Plus results,
negative and indeterminate QFT-Plus categories were
combined to give a binary variable. Logistic regression
was used to determine odds ratios (ORs), 95%CIs and
P values from the likelihood ratio test. Age was
considered a forced variable a priori. Due to the small
number of negative/indeterminate results, a multivar-
iable analysis could not be undertaken. The analysis
was therefore limited to a univariate analysis consist-
ing of base models (each factor adjusted for age) alone.
Results are presented following STARD (Standards for
Reporting of Diagnostic Accuracy) guidelines.19
Ethics approval
Ethics approval for the study was obtained from the
Biomedical Research Ethics Committees of the Uni-
versity of Zambia, Lusaka, Zambia, and the London
School of Hygiene & Tropical Medicine, London, UK.
RESULTS
A total of 108 pulmonary TB patients were recruited
(Figure 1). The median age of the 104 patients with
data was 32 years (interquartile range [IQR] 27–38);
76/104 (73%) were male and 104/104 (100%) were
of Black African ethnicity (Table 1). Over half (55/
104, 53%) had a BMI ,18.5 kg/m2 and 68/108
(63%) were HIV-co-infected.
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QFT-Plus sensitivity
Ninety patients had positive QFT-Plus results, 11
were negative and seven had indeterminate results at
enrolment, giving an overall sensitivity of 83%
(95%CI 75–90). The median TB1 and TB2 concen-
trations, minus the nil background IFN-c concentra-
tions (TB1-nil and TB2-nil), were respectively 2.00
(IQR 0.45–7.50) and 3.81 (IQR 0.59–10.00) IU/ml (P
, 0.001) (Appendix Figure A).* When the overall
results were stratified by antigen tubes, 6/24 (25%)
negative/indeterminate results on TB1 were positive
on TB2 (Table 2).
The sensitivity of QFT-Plus among PLHIV was
similar to that among those who were HIV-negative
(85%, 95%CI 75–93, and 80%, 95%CI 64–91,
respectively, P ¼ 0.59; Table 3). Among PLHIV,
sensitivity was lower with CD4 cell counts ,100
cells/ll than with CD4 7100 cells/ll (50%, 95%CI
16–84 and 89%, 95%CI 75–96, respectively, P ¼
0.02). QFT-Plus sensitivity was lower in those who
were underweight than in those who were normal or
Figure 1 Patients with pulmonary TB enrolled in the study: HIV status, microbiology results and
QuantiFERONW-TB Gold Plus results. TB¼ tuberculosis; HIV¼ human immunodeficiency virus.
Table 1 Characteristics of pulmonary TB patients (n¼ 108)
Characteristic
Total (n ¼ 108)
n (%)*†
Age, years, median [IQR] (n ¼ 104) 32 [27–38]
Male sex (n ¼ 104) 76 (73.1)
Race: Black African (n ¼ 104) 104 (100.0)
Previous TB (n ¼ 104) 18 (17.3)
HIV-positive 68 (63.0)
CD4 cell count category, cells/ll (n ¼ 52/68)‡
,100 8 (15.4)
100–199 11 (21.1)
200–349 20 (38.5)
7350 13 (25.0)
CD4 cell count, cells/ll, median [IQR] (n ¼ 52/68)‡ 246.0 [158.5–344.5]
CD8 cell count, cells/ll, median [IQR] (n ¼ 52/68)‡ 764.0 [551.0–1228.5]
CD3 cell count, cells/ll, median [IQR] (n ¼ 52/68)‡ 1140.5 [766.0–1574.0]
On antiretroviral therapy (n ¼ 64/68)§ 28 (43.8)
Body mass index, kg/m2 (n ¼ 104)
,18.5 55 (52.9)
18.5–24.9 48 (46.1)
725 1 (1.0)
Symptoms (n ¼ 104)
Cough 103 (99.0)
Fever 60 (57.7)
Night sweats 83 (79.8)
Weight loss 96 (92.3)
Any one of cough, fever, night sweats and weight loss 104 (100.0)
*Denominator¼ 108 unless otherwise indicated.
† Figures shown are proportions unless otherwise indicated.
‡ Restricted to the 68 PLHIV, only 52 of whom had CD4 cell count results.
§ Restricted to the 68 PLHIV, only 64 of whom had information on ART use.
TB¼ tuberculosis; IQR¼ interquartile range; HIV¼human immunodeficiency virus; PLHIV¼people living with HIV; ART
¼ antiretroviral therapy.
*The appendix is available in the online version of this article, at
http://www.ingentaconnect.com/content/iuatld/ijtld/2017/
00000021/00000006/art00015
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overweight (76%, 95%CI 63–87 and 92%, 95%CI
80–98, respectively, P¼ 0.04).
The median IFN-c concentration was higher in
TB2 than in TB1, irrespective of HIV status (Figure
2). The median TB1-nil and TB2-nil concentrations
among those who were HIV-negative was respectively
1.61 (IQR 0.43–5.74) and 2.47 IU/ml (IQR 0.67–
10.00), i.e., the difference in median concentration
was 0.86 IU/ml (P , 0.001). Among PLHIV it was
respectively 2.32 (IQR 0.45–7.87) and 4.42 IU/ml
(IQR 0.58–9.77), i.e., the difference in median
concentration was 2.1 IU/ml (P , 0.001). Among
those who were HIV-negative, 2/10 (20%) negative/
indeterminate results on TB1 were positive on TB2
(Appendix Table A.1). Among PLHIV, 4/14 (29%)
patients with negative/indeterminate results on TB1
were positive on TB2 (Appendix Table A.2). The
proportion positive on TB1 and TB2 did not vary by
HIV status; respectively 30/40 (75%) and 54/68
(79%) HIV-negative individuals and PLHIV were
positive on TB1 (P ¼ 0.88), and respectively 32/40
(80%) and 58/68 (85%) were positive on TB2 (P ¼
0.66). When indeterminates were excluded, the
overall QFT-Plus sensitivity was 89% (95%CI 81–
94, n¼ 90/101; Appendix Table A.3).
Negative/indeterminate enrolment QFT-Plus results
The characteristics of 18 patients who were QFT-
Plus-negative or indeterminate at enrolment are
shown separately in Appendix Table A.4. The median
age of these patients was 33 years (IQR 30–37); 14/17
(82%) were male and 17/17 (100%) reported at least
one of cough, fever, night sweats or unintentional
weight loss. Most (13/17, 76%) were underweight. In
total, 10/18 (56%) were HIV-positive; the median
CD4 and CD8 cell counts of 9 patients with results
were respectively 187 (IQR 37–209) and 669 cells/ll
(IQR 424–1289). The median TB1-nil and TB2-nil
concentrations at enrolment were respectively 0.14
Table 2 Overall test results (positive, negative, indeterminate)
of pulmonary tuberculosis patients by QuantiFERONW-TB Gold
Plus tube (n¼ 108)
Tube
TB2
TotalPositive Negative Indeterminate
TB1
Positive 84 0 0 84
Negative 3 11 0 14
Indeterminate 3 0 7 10
Total 90 11 7 108
Table 3 Distribution of QuantiFERONW-TB Gold Plus results by patient characteristics and univariate logistic regression analysis of
factors associated with positive QFT-Plus results in pulmonary TB patients (n¼ 108)
Characteristic
Distribution of QFT-Plus results* Characteristics associated with QFT-Plus results‡
Indeterminate Negative Positive
P value†
Univariate analysis§¶
P value#n (%) n (%) n (%) OR (95%CI)
Age, years (n ¼ 104)
18–29 1 (2.9) 3 (8.8) 30 (88.2) 0.61 1 0.55
30–39 4 (8.2) 6 (12.2) 39 (79.6) 0.52 (0.15–1.82)**
740 1 (4.8) 2 (9.5) 18 (85.7) 0.80 (0.16–3.99)**
Sex (n ¼ 104)
Male 6 (7.9) 8 (10.5) 62 (81.6) 0.55 1 0.34
Female 0 3 (10.7) 25 (89.3) 1.86 (0.49–7.13)
Previous TB (n ¼ 104)
No 4 (4.7) 8 (9.3) 74 (86.0) 0.17 1 0.17
Yes 2 (11.1) 3 (16.7) 13 (72.2) 0.41 (0.12–1.40)
HIV status
Positive 4 (5.9) 6 (8.8) 58 (85.3) 0.59 1 0.31
Negative 3 (7.5) 5 (12.5) 32 (80.0) 0.57 (0.20–1.66)
CD4 cell count category (n ¼ 52/68)††
7100 cells/ll 2 (4.6) 3 (6.8) 39 (88.6) 0.02 1 0.05
,100 cells/ll 2 (25.0) 2 (25.0) 4 (50.0) 0.15 (0.02–0.96)
On antiretroviral therapy (n ¼ 64/68)††
No 1 (2.8) 4 (11.1) 31 (86.1) 1.00 1 1.00
Yes 2 (7.1) 2 (7.1) 24 (85.7) 1.00 (0.23–4.26)
Body mass index, kg/m2 (n ¼ 104)
718.5 2 (4.1) 2 (4.1) 45 (91.8) 0.04 1 0.02
,18.5 4 (7.3) 9 (16.4) 42 (76.4) 0.27 (0.08–0.91)
*Denominator¼ 108 unless otherwise indicated.
† Positive and negative/indeterminate categories compared using Fisher’s exact test.
‡ Negative and indeterminate QFT-Plus results combined, to give a binary variable with positive and negative/indeterminate categories.
§ Univariate analysis consists of base models, each characteristic adjusted for age (forced variable) alone.
¶ Univariate analysis restricted to n¼ 104 unless otherwise indicated.
# P values from the likelihood ratio test.
**Only age included in the model.
††Only among people living with HIV.
TB¼ tuberculosis; OR¼odds ratio; CI¼confidence interval; HIV¼ human immunodeficiency virus.
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(IQR 0.03–0.27) and 0.24 IU/ml (IQR 0.08–0.32)
(Appendix Table A.5).
On univariate analysis (Table 3), CD4 cell count
,100 cells/ll (OR 0.15, 95%CI 0.02–0.96, P¼0.05)
and being underweight (OR 0.27, 95%CI 0.08–0.91,
P ¼ 0.02) were associated with decreased odds of
positive QFT-Plus results.
Of 18 patients with negative/indeterminate enrol-
ment QFT-Plus results, seven (39%) underwent testing
at 1–2 months post-enrolment, five of whom (71%)
were positive on repeated testing (4/6, 67%, with
negative and 1/1, 100%, with indeterminate enrol-
ment results; Appendix Table A.5). The median TB1-
nil and TB2-nil concentrations at enrolment and 1–2
months post-enrolment for two patients who were not
positive on repeat testing were respectively 0.03 (IQR
0.02 to 0.08) and 0.10 IU/ml (IQR 0.06–0.14), and
0.08 (IQR 0.06–0.10) and 0.09 IU/ml (IQR 0.05–
0.13). Among five patients who were positive on
repeat testing, these were respectively 0.20 (IQR 0.16–
0.27) and 0.31 IU/ml (IQR 0.25–0.33) at enrolment,
and 0.83 (IQR 0.47–1.53) and 0.97 (IQR 0.72–1.21)
IU/ml at 1–2 months post-enrolment.
DISCUSSION
This is the first study to describe the sensitivity of the
new QFT-Plus assay for TB in a population with a
high prevalence of HIV. The assay’s overall sensitivity
was maintained, regardless of HIV status. However,
sensitivity was lower among PLHIV with severe
immunosuppression.
A multicentre study across six European hospitals
found a QFT-Plus sensitivity of 86% (102/119;
95%CI 78-91%) for bacteriologically confirmed
TB,20 which is comparable to our findings. All four
patients who were TB-HIV-co-infected had positive
QFT-Plus results.20 While these numbers are too
small to draw any firm conclusions, they corroborate
our findings of high QFT-Plus sensitivity among
PLHIV. QFT-Plus specificity among low-risk subjects
in Europe was 97% (95%CI 92–99).20 Similar results
have been reported from Germany and Japan, where
head-to-head comparisons of QFT-Plus and QGIT
among predominantly immunocompetent patients
showed similar test sensitivities.21,22
A study using the same methods as our study was
conducted by Raby et al. at the same health facility in
2007 to determine QGIT and TST sensitivity in a
similar population.11 The proportion of TB-HIV-co-
infected patients and the median CD4 cell counts
among PLHIV were similar in both studies (Table 4).
Overall QFT-Plus sensitivity in our study was similar
to QGIT and TST sensitivity; however, unlike QGIT
and TST, overall QFT-Plus sensitivity was not
affected by HIV status. Studies of QGIT in a number
of countries have shown a lower overall assay
sensitivity among PLHIV;9 our findings are thus
contrary to these. While QFT-Plus sensitivity, like
QGIT, was lower in PLHIV with CD4 cell counts
,100 cells/ll, the point estimate suggests that QFT-
Plus sensitivity may be higher in those with CD4 cell
counts ,100 cells/ll than with QGIT. However, the
very small number in the strata precludes any firm
conclusions being drawn. Larger studies with direct
head-to-head comparisons of QFT-Plus and QGIT
among severely immunosuppressed patients are
needed to investigate this further.
Like QGIT, the QFT-Plus TB1 tube elicits a CD4-
mediated immune response alone. TB1 sensitivity was
not affected by HIV status. However, it is not possible
to directly infer QGIT sensitivity based on TB1
sensitivity, given the changes that have been made
to the antigens and their formulation. Studies with
direct head-to-head comparisons of QFT-Plus and
QGIT in high HIV prevalence settings are needed to
investigate this further.
Figure 2 Dot plot of TB1 and TB2, minus the nil background
IFN-c concentration among pulmonary TB patients tested using
the QuantiFERONW-TB Gold Plus assay, stratified by HIV status (n
¼ 108 with known HIV status). A) HIV-negative pulmonary TB
patients (n¼40); B) HIV-positive pulmonary TB patients (n¼68).
Each dot represents the TB1 minus the nil background IFN-c
concentration (on the left) and the TB2 minus the nil
background IFN-c concentrations (on the right), per person.
- - - - - - - - ¼ IFN-c concentration of 0.35 IU/ml;þþþþ¼median
IFN-c concentration in IU/ml. IU ¼ international unit; IFN-c ¼
interferon-gamma; TB ¼ tuberculosis; HIV ¼ human immuno-
deficiency virus.
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The higher QFT-Plus sensitivity among PLHIV
could have important clinical and policy implica-
tions. Given the similar performance but higher costs
of IGRAs compared to TST, the World Health
Organization recommended the continued use of
TST in low- and middle-income countries in 2011.23
This stance may need to be re-evaluated in the light of
our findings, taking into consideration the reproduc-
ibility of the results, direct head-to-head comparisons
of QGIT and QFT-Plus, including in severely immu-
nosuppressed patients, costs and logistics. In addi-
tion, an ideal test for LTBI should be able to predict
LTBI patients who will progress to develop active TB.
The predictive value of QFT-Plus for active TB
therefore needs to be further investigated.
When compared with QGIT in the study by Raby et
al.,11 the proportion with indeterminate results on
QFT-Plus was lower (Table 4). Indeterminate results
may be due to technical errors in sample handling and
processing, or immunosuppression of lymphocyte cell
lines due to advanced and severe HIV and/or TB.7,16
Improvements in laboratory procedures over time
may therefore partly explain the differences observed.
Likewise, earlier diagnosis of HIV and/or TB would
result in a shift from indeterminate to positive results.
However, TB-HIV-co-infected patients had similar
levels of HIV-associated immunosuppression in both
studies, suggesting that this is less likely. Finally,
targeting both CD8- and CD4-mediated responses by
QFT-Plus can increase IFN-c levels sufficiently, even
in the presence of a low IFN-c response to mitogen, as
seen by the three results indeterminate on TB1 which
were positive on TB2.
In contrast, negative results indicate an immune
response to the positive control, without detectable T-
lymphocyte responses to M. tuberculosis-specific anti-
gens.With QFT-Plus, as both CD4- and CD8-mediated
IFN-c responses are targeted, a decrease in negative
results was anticipated. However, the proportions with
negative QFT-Plus were similar to those of QGIT
(Table 4).11 The exact mechanism underlying these
negative results are unclear. False-positive microbio-
logical results may play a role; however, studies have
shown that the specificity of a positive smear or Xpert
for M. tuberculosis is high in high TB prevalence
settings.24–26 Representative data on the proportion of
smear- or Xpert-positive pulmonary TB patients who
are culture-positive for M. tuberculosis in our setting
are not available. On univariate analysis, negative/
indeterminate QFT-Plus results were associated with a
low BMI, which in the context of TB suggests advanced
disease that may be associated with TB-specific
immune paresis,27 resulting in negative responses to
M. tuberculosis-specific antigens but positive responses
to mitogen. This hypothesis is corroborated by the
finding that nearly 70% of negative results at enrol-
ment had converted to positive at 1–2 months
following treatment. Studies immunologically charac-
terising negative responses are needed to confirm this.
However, the IFN-c concentrations in a number of
these samples were close to the manufacturer’s
threshold, and may represent fluctuations in values
around the threshold. Repeat testing of the samples
may therefore have yielded positive results.
Our study has several limitations. It was small and
undertaken to explore QFT-Plus sensitivity in a high
HIV prevalence setting; CIs around point estimates are
therefore wide. Culture was not performed on TB
patients. A direct head-to-head comparison of QGIT
and QFT-Plus was not undertaken. The results cannot
be generalised to children, as only adults were included.
Table 4 Comparing the performance of QGITassay, the TSTand QFT-Plus among adult (age718
years) pulmonary TB patients
Study features
Raby et al.11
QFT-PlusQGIT TST
(n ¼ 112) (n ¼ 92) (n ¼ 108)
Case definition Smear þve; within
1 month of treatment
Smear or Xpert þve within
2 days of treatment
TB-HIV co-infection, % 61 63
Median CD4 cell count among PLHIV, cells/ll 212 246
% (95%CI) % (95%CI) % (95%CI)
Overall
Sensitivity 74 (66–82) 67 (58–77) 83 (75–90)
Quantiferon-negative 12 (6–19) NA 10 (5–17)
Quantiferon-indeterminate 14 (8–22) NA 6 (3–13)
Sensitivity by
HIV-positive 63 (50–74) 55 (40–70) 85 (75–93)
HIV-negative 84 (71–96) 81 (62–92) 80 (64–91)
CD4 cell count, cells/ll
,100 23 (5–54) — 50 (16–84)
100–199 70 (46–88) — 91 (59–99)
200–349 74 (52–90) — 85 (62–97)
7350 88 (75–95) — 92 (64–99)
QGIT¼QuantiFERONW-TB Gold In-Tube assay; TST¼ tuberculin skin test; QFT-Plus¼QuantiFERONW-TB Gold Plus; TB¼
tuberculosis;þve¼ positive; PLHIV¼ people living with HIV; CI¼ confidence interval; NA¼ not applicable.
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CONCLUSION
QFT-Plus sensitivity was similar to QGIT and TST
sensitivity for pulmonary TB, used as a surrogate for
LTBI. While overall sensitivity was not affected by
HIV status, the sensitivity was lower among PLHIV
with severe immunosuppression. Work is needed to
understand the assay’s predictive value for active TB.
Acknowledgements
QIAGEN provided the QuantiFERONw-TB Gold Plus kits free of
charge for use in this study. They had no role in the study design,
collection, analysis or interpretation of data, manuscript prepara-
tion or decision to publish findings. The views expressed are solely
those of the study authors.
SLB is supported by aWellcome Trust Clinical Research Training
Fellowship through the Clinical PhD programme at the London
School of Hygiene & Tropical Medicine, London, UK (100141/Z/
12/Z).
Declaration of interests: All authors declare that QIAGEN
provided non-financial support by providing the QuantiFERONw-
TB Gold Plus kits free of charge to use in the study. HA, BK, KM,
DKM, KC and SF received grants from National Institutes for
Health, Bethesda,MD, USA, during the conduct of the study, which
partially paid their salaries. SLB received a grant from the
Wellcome Trust, London, UK, which paid her salary during the
conduct of the study.
This is an open access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the
original author and source are credited.
References
1 Sonnenberg P, Glynn J R, Fielding K, Murray J, Godfrey-
Faussett P, Shearer S. How soon after infection with HIV does
the risk of tuberculosis start to increase? A retrospective cohort
study in South African gold miners. J Infect Dis 2005; 191: 150–
158.
2 Corbett E L, Marston B, Churchyard G J, De Cock K M.
Tuberculosis in sub-Saharan Africa: opportunities, challenges,
and change in the era of antiretroviral treatment. Lancet 2006;
367: 926–937.
3 Churchyard G J, Fielding K L, Lewis J J, et al. A trial of mass
isoniazid preventive therapy for tuberculosis control. N Engl J
Med 2014; 370: 301–310.
4 Getahun H, Granich R, Sculier D, et al. Implementation of
isoniazid preventive therapy for people living with HIV
worldwide: barriers and solutions. AIDS 2010; 24 (Suppl 5):
S57–S65.
5 Rangaka M X, Cavalcante S C, Marais B J, et al. Controlling
the seedbeds of tuberculosis: diagnosis and treatment of
tuberculosis infection. Lancet 2015; 386: 2344–2353.
6 Getahun H, Matteelli A, Chaisson R E, Raviglione M. Latent
Mycobacterium tuberculosis infection. N Engl J Med 2015;
372: 2127–2135.
7 Pai M, Denkinger CM, Kik S V, et al. Gamma interferon release
assays for detection of Mycobacterium tuberculosis infection.
Clin Microbiol Rev 2014; 27: 3–20.
8 Metcalfe J Z, Everett C K, Steingart K R, et al. Interferon-
gamma release assays for active pulmonary tuberculosis
diagnosis in adults in low- and middle-income countries:
systematic review and meta-analysis. J Infect Dis 2011; 204
(Suppl 4): S1120–S1129.
9 Santin M, Munoz L, Rigau D. Interferon-gamma release assays
for the diagnosis of tuberculosis and tuberculosis infection in
HIV-infected adults: a systematic review and meta-analysis.
PLOS ONE 2012; 7: e32482.
10 BoomWH, Canaday D H, Fulton S A, Gehring A J, Rojas R E,
Torres M. Human immunity to M. tuberculosis: T-cell subsets
and antigen processing. Tuberculosis 2003; 83: 98–106.
11 Raby E, Moyo M, Devendra A, et al. The effects of HIVon the
sensitivity of a whole blood IFN-gamma release assay in
Zambian adults with active tuberculosis. PLOS ONE 2008; 3:
e2489.
12 Turner J, Dockrell HM. Stimulation of human peripheral blood
mononuclear cells with live Mycobacterium bovis BCG
activates cytolytic CD8þ T cells in vitro. Immunology 1996;
87: 339–342.
13 Brookes R H, Pathan A A, McShane H, Hensmann M, Price D
A, Hill AV. CD8þT cell-mediated suppression of intracellular
Mycobacterium tuberculosis growth in activated human
macrophages. Eur J Immunol 2003; 33: 3293–3302.
14 Lewinsohn D A, Winata E, Swarbrick G M, et al.
Immunodominant tuberculosis CD8 antigens preferentially
restricted by HLA-B. PLOS pathog 2007; 3: 1240–1249.
15 Lalvani A, Brookes R, Wilkinson R J, et al. Human cytolytic
and interferon gamma-secreting CD8þ T lymphocytes specific
forMycobacterium tuberculosis. Proc Natl Acad Sci USA 1998;
95: 270–275.
16 Qiagen. QuantiFERONw-TB Gold Plus (QFT-Plus) ELISA
package insert. Hilden, Germany: Qiagen, 2015. http://www.
quantiferon.com/irm/content/PI/QFT/PLUS/2PK-Elisa/UK.pdf.
Accessed March 2017.
17 Ministry of Health. Zambia National Guidelines for HIV
counselling and testing 2006. Lusaka, Zambia: MoH, 2006.
http://hivstar.lshtm.ac.uk/files/2016/05/Zambia-National-
Guidelines-for-HIV-Counsellig-and-Testing2006.pdf. Accessed
March 2017.
18 World Health Organization. Global database on body mass
index 2015. Geneva, Switzerland: WHO, 2015. http://apps.
who.int/bmi/index.jsp?introPage¼intro_3.html.
19 Bossuyt P M, Reitsma J B, Bruns D E, et al. STARD 2015: an
updated list of essential items for reporting diagnostic accuracy
studies. BMJ 2015; 351: h5527.
20 Barcellini L, Borroni E, Brown J, et al. First independent
evaluation of QuantiFERON-TB Plus performance. Eur Respir
J 2016; 47: 1587–1590.
21 Yi L, Sasaki Y, Nagai H, et al. Evaluation of QuantiFERON-TB
Gold Plus for Detection of Mycobacterium tuberculosis
infection in Japan. Sci Rep 2016; 6: 30617.
22 Hoffmann H, Avsar K, Gores R, Mavi S C, Hofmann-Thiel S.
Equal sensitivity of the new generation QuantiFERON-TB
Gold plus in direct comparison with the previous test version
QuantiFERON-TB Gold IT. Clin Microbiol Infect 2016; 22:
701–703.
23 World Health Organization. Use of tuberculosis interferon
gamma release assays (IGRAs) in low- and middle-income
countries: policy statement. WHO/HTM/TB/2011.18. Geneva,
Switzerland: WHO, 2011. http://www.who.int/tb/features_
archive/policy_statement_igra_oct2011.pdf. Accessed March
2017.
24 Perkins M D. New diagnostic tools for tuberculosis. Int J
Tuberc Lung Dis 2000; 4 (Suppl 2): S182–188.
25 Boehme CC, Nicol MP, Nabeta P, et al. Feasibility, diagnostic
accuracy, and effectiveness of decentralised use of the Xpert
MTB/RIF test for diagnosis of tuberculosis and multidrug
resistance: a multicentre implementation study. Lancet 2011;
377: 1495–1505.
26 Steingart K R, Sohn H, Schiller I, et al. XpertwMTB/RIF assay
for pulmonary tuberculosis and rifampicin resistance in adults.
Cochrane Database Syst Rev 2013; 1: CD009593.
27 Boussiotis V A, Tsai E Y, Yunis E J, et al. IL-10-producing T
cells suppress immune responses in anergic tuberculosis
patients. J Clin Invest 2000; 105: 1317–1325.
696 The International Journal of Tuberculosis and Lung Disease
APPENDIX
Table A.1 Overall test results (positive, negative,
indeterminate) by QuantiFERONW-TB Gold Plus tubes for N¼40
HIV negative pulmonary TB patients
Tube
TB2
TotalPositive Negative Indeterminate
TB1
Positive 30 0 0 30
Negative 1 5 0 6
Indeterminate 1 0 3 4
Total 32 5 3 40
Table A.2 Overall test results (positive, negative,
indeterminate) by QuantiFERONW-TB Gold Plus tubes for people
living with HIV/AIDS with pulmonary TB (n¼ 68)
Tube
TB2
TotalPositive Negative Indeterminate
TB1
Positive 54 0 0 54
Negative 2 6 0 8
Indeterminate 2 0 4 6
Total 58 6 4 68
HIV ¼ human immunodeficiency virus; AIDS ¼ acquired immune-deficiency
syndrome.
Table A.3 Distribution of QFT-Plus results by patient
characteristics for pulmonary TB patients with negative and
positive QFT-Plus results (n¼ 101)
Characteristic
Distribution of QFT-Plus results*
Negative
(n ¼ 11, 10.9%)
Positive
(n ¼ 90, 89.1%)
n (%) n (%)
Age, years (n ¼ 98)
18–29 3 (9.1) 30 (90.9)
30–39 6 (13.3) 39 (86.7)
740 2 (10.0) 18 (90.0)
Sex (n ¼ 98)
Male 8 (11.4) 62 (88.6)
Female 3 (10.7) 25 (89.3)
Previous TB (n ¼ 98)
No 8 (9.8) 74 (90.2)
Yes 3 (18.8) 13 (81.2)
HIV status
Positive 6 (9.4) 58 (90.6)
Negative 5 (13.5) 32 (86.5)
CD4 cell count category (n ¼ 48/64)
7100 cells/ll 3 (7.1) 39 (92.9)
,100 cells/ll 2 (33.3) 4 (66.7)
On antiretroviral therapy (n ¼ 61/64)
No 4 (11.4) 31 (88.6)
Yes 2 (7.7) 24 (92.3)
Body mass index, kg/m2(n ¼ 98)
718.5 2 (4.3) 45 (95.7)
,18.5 9 (17.7) 42 (82.3)
*Denominator¼ 101 unless otherwise indicated.
QFT-Plus ¼ QuantiFERONW-TB Gold Plus; TB ¼ tuberculosis; HIV ¼ human
immunodeficiency virus.
Figure A Dot plot of TB1 and TB2, minus the nil background
IFN-c concentration for pulmonary TB patients who underwent
QuantiFERONW-TB Gold Plus testing (n ¼ 108). Each dot
represents the TB1 minus the nil background IFN-c concentra-
tion (on the left) and the TB2 minus the nil background IFN-c
concentrations (on the right), per person. — ¼ IFN-c concen-
tration¼ 0.35 IU/ml;þþ¼median IFN-c concentration in IU/ml.
IFN-c¼ interferon-gamma; IU¼ international unit.
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Table A.4 Characteristics of pulmonary TB patients by QuantiFERONW-TB Gold Plus status (n¼ 108)
Characteristic
QuantiFERONW-TB Gold Plus status
Indeterminate
(n ¼ 7)
Negative
(n ¼ 11)
Positive
(n ¼ 90)
n (%)*† n (%)†‡ n (%)†§
Age, years, median [IQR] (6 indeterminate, 11 negative, 87 positive) 32.5 [31–37] 33 [25–39] 32 [27–38]
Male sex (6 indeterminate, 11 negative, 87 positive) 6 (100) 8 (72.7) 62 (71.3)
Black race (6 indeterminate, 11 negative, 87 positive) 6 (100) 11 (100) 87 (100)
Previous TB (6 indeterminate, 11 negative, 87 positive) 2 (33.3) 3 (27.3) 13 (14.9)
HIV-positive 4 (57.1) 6 (54.6) 58 (64.4)
CD4 cell count, cells/ll, median [IQR] (4 indeterminate, 5 negative, 43 positive) 112 [35–198] 201 [53–263] 258 [169–363]
CD8 cell count, cells/ll, median [IQR] (4 indeterminate, 5 negative, 43 positive) 812.5 [283.5–1245] 669 [542–1322] 775 [602–1226]
CD3 cell count, cells/ll, median [IQR] (4 indeterminate, 5 negative, 43 positive) 869.5 [427.5–1387] 658 [611–2019] 1156 [828–1593]
On antiretroviral treatment (3 indeterminate, 6 negative, 55 positive) 2 (66.7) 2 (33.3) 24 (43.6)
BMI, kg/m2 (6 indeterminate, 11 negative, 87 positive)
,18.5 4 (66.7) 9 (81.8) 42 (48.3)
18.5–24.9 2 (33.3) 2 (18.2) 44 (50.6)
725 0 0 1 (1.1)
Symptoms (6 indeterminate, 11 negative, 87 positive)
Cough 6 (100) 11 (100) 86 (98.9)
Fever 5 (83.3) 8 (72.7) 47 (54.0)
Night sweats 6 (100) 9 (81.8) 68 (78.2)
Weight loss 6 (100) 11 (100) 79 (90.8)
Any one of cough, fever, night sweats and weight loss 6 (100) 11 (100) 87 (100)
*Denominator¼ 7 unless otherwise indicated.
† Figures shown are proportions unless otherwise indicated.
‡ Denominator¼ 11 unless otherwise indicated.
§ Denominator¼ 90 unless otherwise indicated.
TB¼ tuberculosis; IQR¼ interquartile range; BMI¼ body mass index.
Table A.5 QuantiFERONW-TB Gold Plus values at enrolment and 1–2 months post-enrolment, where available, for individuals who
were indeterminate or negative at enrolment (n¼ 18)
Patient
HIV
status
Enrolment results 1–2 month post-enrolment results
Nil
IU/ml
TB1 minus
nil IU/ml
TB2 minus
nil IU/ml
Mitogen
minus
nil IU/ml Result
Nil
IU/ml
TB1 minus
nil IU/ml
TB2 minus
nil IU/ml
Mitogen
minus
nil IU/ml Result
1 Negative 0.23 0.16 0.31 0.21 Indeterminate 0.32 7.32 8.09 2.02 Positive
2 Negative 0.22 0.02 0.06 9.41 Negative 0.12 0.06 0.05 10 Negative
3 Positive 0.13 0.27 0.23 3.66 Negative 0.19 0.47 0.51 3.78 Positive
4 Negative 0.12 0.12 0.33 6.65 Negative 0.13 0.37 0.72 10 Positive
5 Positive 0.36 0.20 0.25 4.69 Negative 0.22 1.53 0.97 10 Positive
6 Negative 0.19 0.27 0.33 4.10 Negative 0.17 0.83 1.21 3.52 Positive
7 Positive 0.23 0.08 0.14 0.53 Negative 0.25 0.1 0.13 0.54 Negative
8 Negative 10 1.86 1.05 3.12 Indeterminate
9 Positive 10 5.52 6.15 0.45 Indeterminate
10 Positive 0.15 0.03 0.09 0.12 Indeterminate
11 Positive 0.13 0.02 0.05 0.07 Indeterminate
12 Positive 0.25 0.02 0.05 0.06 Indeterminate
13 Negative 0.25 0.03 0.07 0.02 Indeterminate
14 Positive 0.31 0.18 0.28 0.91 Negative
15 Negative 0.16 0.17 0.32 0.77 Negative
16 Positive 0.46 0.13 0.26 10 Negative
17 Negative 0.19 0.28 0.14 2.88 Negative
18 Positive 0.15 0.05 0.08 1.42 Negative
HIV¼ human immunodeficiency virus; IU¼ international unit.
ii The International Journal of Tuberculosis and Lung Disease
R E S U M E
CONT EX T E e t OB J E C T I F S : Examiner la sensibilite´ du
nouveau test de libe´ration de l’interfe´ron gamma
(IGRA), QuantiFERONw-TB Gold Plus (QFT-Plus),
pour la tuberculose (TB) active (utilise´e comme
substitut de l’infection tuberculeuse latente) dans une
centre TB de Zambie.
S CH E´MA : Des patients adultes conse´cutifs (aˆge 718
ans) atteints de TB pulmonaire a` frottis positif ou Xpert
positif ont e´te´ recrute´s entre juin 2015 et mars 2016.
Leur sang veineux a e´te´ teste´ avec QFT-Plus. La
sensibilite´ a e´te´ le nombre de re´sultats positifs sur le
total teste´. Une re´gression logistique a permis d’explorer
les facteurs associe´s avec la positivite´ de QFT-Plus.
R E´ S U LTAT S : Parmi 108 patients (aˆge me´dian 32 ans,
intervalle interquartile 27–38 ; 73% d’hommes et 63%
positifs au virus de l’immunode´ficience humaine [VIH]),
il y a eu 90 re´sultats de QFT-Plus positifs, 11 ne´gatifs et
sept inde´termine´s, soit une sensibilite´ de 83% (IC95%
75–90). Il n’y a pas eu de diffe´rence de sensibilite´ en
fonction du statut VIH (VIH positifs 85% ; IC95% 75–
93 ; n¼68 et VIH ne´gatifs 80% ; IC95% 64–91 ; n¼40 ;
P¼ 0,59). Dans les mode`les ajuste´s sur l’aˆge seulement,
la nume´ration des CD4 ,100 cellules/ll (OR 0,15 ;
IC95% 0,02–0,96 ; P ¼ 0,05) et l’indice de masse
corporelle ,18,5 kg/m2 (OR 0,27 ; IC95% 0,08–0,91 ;
P ¼ 0,02) ont e´te´ associe´s avec une diminution de la
probabilite´ de re´sultats positifs de QFT-Plus.
CONC LU S I ON : La sensibilite´ d’ensemble de QFT-Plus
est similaire a` celle du test cutane´ a` la tuberculine et a`
d’autres IGRA. Si la sensibilite´ d’ensemble n’est pas
affecte´e par le statut VIH, elle a cependant e´te´ plus faible
parmi les personnes vivant avec le VIH/SIDA (syndrome
d’immunode´ficience acquise) atteints
d’immunosuppression grave.
R E S UM E N
MARCO DE R E F E R ENC I A Y OB J E T I VO S: Investigar la
sensibilidad de una nueva prueba de liberacio´n de
interfero´n-gama (IGRA), la QuantiFERONw-TB Gold
Plus (QFT-Plus), en la deteccio´n de la tuberculosis (TB)
activa (utilizada como indicador indirecto de la
infeccio´n tuberculosa latente) en un consultorio de TB
en Zambia.
M E´ TODO: Se incluyeron en estudio los pacientes adultos
(a partir de los 18 an˜os de edad) consecutivos con
diagno´stico de TB pulmonar y un resultado positivo de
la baciloscopia o de la prueba XpertwMTB/RIF de junio
del 2015 a marzo del 2016. Se practico´ la prueba QFT-
Plus en una muestra de sangre perife´rica. La sensibilidad
se definio´ como el nu´mero de resultados positivos sobre
el total de pruebas realizadas. Mediante un ana´lisis de
regresio´n logı´stica se analizaron los factores asociados
con un resultado positivo de la prueba QFT-Plus.
R E SU LTADOS: De los 108 pacientes (mediana de la
edad 32 an˜os; amplitud intercuartı´lica de 27 a 38; 73%
de sexo masculino y 63% positivos frente al virus de la
inmunodeficiencia humana [VIH]), 90 obtuvieron un
resultado positivo de la prueba QFT-Plus, 11 pacientes
un resultado negativo y en 7 casos el resultado fue
indefinido; la sensibilidad fue 83% (IC95% de 75 a 90).
No se observo´ ninguna diferencia de sensibilidad en
funcio´n de la situacio´n frente al VIH (VIH positivos
85% ; IC95% de 75 a 93; n¼68 y VIH negativos 80% ;
IC95% de 64 a 91; n ¼ 40; P ¼ 0,59). En los modelos
ajustados segu´n la edad u´nicamente, los factores
asociados con una menor probabilidad de obtener un
resultado positivo de la prueba QFT-Plus fueron un
recuento de linfocitos CD4 ,100 ce´lulas/ll (OR 0,15;
IC95% de 0,02 a 0,96; P ¼ 0,05) y un ı´ndice de masa
corporal,18,5 kg/m2 (OR 0,27; IC95% de 0,08 a 0,91;
P¼ 0,02).
CONC LU S I O´ N: La sensibilidad global de la prueba
QFT-Plus es equivalente a la sensibilidad de la reaccio´n
tuberculı´nica y de otras IGRA. Esta sensibilidad no se
afecta por la situacio´n frente al VIH, pero fue inferior en
las personas con infeccio´n por el VIH y sı´ndrome de
inmunodeficiencia adquirida que presentaban una
inmunodepresio´n grave.
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